Compare AAT & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAT | IMCR |
|---|---|---|
| Founded | 1967 | 2008 |
| Country | United States | United Kingdom |
| Employees | 208 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2010 | 2016 |
| Metric | AAT | IMCR |
|---|---|---|
| Price | $25.31 | $32.53 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $19.50 | ★ $66.33 |
| AVG Volume (30 Days) | 455.3K | ★ 548.6K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.65% | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | 0.08 | ★ 0.25 |
| Revenue | ★ $436,204,000.00 | $249,428,000.00 |
| Revenue This Year | $4.33 | $14.57 |
| Revenue Next Year | $0.22 | $8.21 |
| P/E Ratio | $315.25 | ★ $126.60 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $17.72 | $27.56 |
| 52 Week High | $25.34 | $40.71 |
| Indicator | AAT | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 70.84 | 69.39 |
| Support Level | $18.23 | $31.02 |
| Resistance Level | N/A | $33.32 |
| Average True Range (ATR) | 0.49 | 1.14 |
| MACD | -0.02 | 0.40 |
| Stochastic Oscillator | 88.95 | 95.79 |
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.